The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular (CV) events, including heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes (T2D) who have established CV disease. Invokana is the first and only oral diabetes…
Data Reinforce Long-Term Safety, Efficacy, and Tolerability Profile of Symtuza
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new 96-week data from the pivotal Phase 3 AMBER study of Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide), a single-tablet regimen (STR) for treatment-naïve and certain virologically suppressed adults living with human immunodeficiency virus type 1 (HIV-1). The 96-week data, which is the continuation of the 48-week results, reinforce the long-term…
Janssen Reinforces Long-Term Efficacy and Safety of Symtuza
The Janssen Pharmaceutical Companies of Johnson & Johnson is unveiling new 96-week data for Symtuza (darunavir 200 mg, cobicistat 150 mg, emtricitabine 200mg, and tenofovir alafenamide 10 mg; D/C/F/TAF), a single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults, in a presentation at IDWeek 2018 in San…